TILs Working Group
@TILsWorkGroup
We are interested in the immune infiltrate in Breast cancer and what it means for treatment and prevention.
You might like
We've recently launched a global survey on the potential use of #TILs for future trial designs and use in daily practice. We would love to hear what you have to say 👇fd7.formdesk.com/BQA/TILs_TNBC_…
Tagging @TILsWorkGroup to amplify this great work
✨✨hot off the press from the #loilab. We show here that pregnancy & breastfeeding is associated with increased T cells in the normal breast and protection against #tnbc #breastcancer moving the role of immunity from treatment to prevention. 👏👏Thanks to @FAndreMD @DrChoueiri…
✨✨hot off the press from the #loilab. We show here that pregnancy & breastfeeding is associated with increased T cells in the normal breast and protection against #tnbc #breastcancer moving the role of immunity from treatment to prevention. 👏👏Thanks to @FAndreMD @DrChoueiri…
Translational data shows that #breastfeeding helps personal immunity improving CD8+ T This work can help to understand better the immune system and breastfeeding mechanisms @LoiSher @OncoAlert #ESMO25 @FernandoOnco
The EU-funded MSCA Doctoral Network “Spatial Crosstalk in Immune-Oncology” (SpaXio) is now officially recruiting 14 PhD students to decipher the metastasis-promoting microenvironment of colon and breast cancer. More info here: tilsinbreastcancer.org/wp-content/upl…
😎if #TIL had been the prespecified biomarker, pembrolizumab might well be approved for this indication. PD-L1 IHC has real technical limitations- patients deserve multiple validated ways to identified immune enriched tumors. #TILs are simple, free & readily available- wait 🤔is…
💫🌟Association of potential biomarkers with clinical outcomes in metastatic TNBC treated with pembrolizumab or chemotherapy 👉 nature.com/articles/s4152… @JavierCortesMD @ProfAnthoG @ASCOPres @Prof_Nadia_H @LoiSher 🧬 KEYNOTE-119 exploratory biomarker analysis 🔹 TILs ≥5% → ↑…
Study across 45 institutions shows AI validity in TIL quantification for melanoma. Reproducible with prognostic validity and open-source. @tznaung 👉 jamanetwork.com/journals/jaman… #AIinPathology #Melanoma #ComputationalPathology
Some studies shows how we can reduce costs based on biomarkers SHORT-HER 9 weeks of trastuzumab is ✅ based TILS 20% or more @TILsWorkGroup @OncoAlert #oncoalertAF @JAMAOnc⤵️ jamanetwork.com/journals/jamao…
Great slide highlighting not only are TILs predictive of pCR...it also translates to being prognostic beyond pCR for good outcome and DFS. Seems like we have a LOT of data on TILs now, why aren't they standardly provided on path reports???🧐 #SABCS24 @SABCSSanAntonio @OncoAlert
🤩🍾10th anniversary TILs-Working Group at @SABCSSanAntonio 2024 - everyone welcome! RSVP here: forms.office.com/Pages/Response…
The largest TILs-Workshop done so far! More than 100 pathologist, residents in training and medical students learning how to score TILs. Organized by the Narayana Medical College, India. Who follows? 💪🏼
🤩Check out latest article in @NatureRevCancer! #TILsInBreastCancer #Researchpaper
Towards targeting the breast cancer immune microenvironment dlvr.it/T9C7GF
Our latest review is out now on targeting #BreastCancer #Immunity #tme #trm #CancerResearch many thanks to @NatureRevCancer @PeterMacCC @PeterMacRes @TILsWorkGroup
Towards targeting the breast cancer immune microenvironment dlvr.it/T9C7GF
📣Out now!! Our latest research on TILs in TNBC is now published in @JAMAOnc! Read the full article here: jamanetwork.com/journals/jamao… #TILsInBreastCancer #JAMAOncology #CancerResearch
Sharing a new breast cancer-focused funding opportunity: AACR-AstraZeneca Breast Cancer Research Fellowship for Endocrine Therapy Research. USD130,000 (2yrs). Closes 15th Aug 24. More details 👇 aacr.org/grants/aacr-as…
Pathologists in >166 countries consulted the TILs-website. Don’t stay behind! 🗺️ #TILs tilsinbreastcancer.org
A global effort by the TILs-WG published in @JAMA_current , one of the 🔝 medical journals worldwide #TILs 👉🏼 jamanetwork.com/journals/jama/…
jamanetwork.com
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
This study of patients with early-stage triple-negative breast cancer not treated with adjuvant or neoadjuvant chemotherapy analyzes the association between tumor-infiltrating lymphocyte levels,...
In patients with early-stage triple-negative breast cancer treated with locoregional therapy only, higher levels of tumor-infiltrating lymphocytes in breast cancer tissue were associated with improved survival. ja.ma/4aCzMeD
United States Trends
- 1. Good Thursday 21.9K posts
- 2. #ProofOfFortification N/A
- 3. Nnamdi Kanu 48.6K posts
- 4. Knicks 13.8K posts
- 5. #GirlPower N/A
- 6. Shamet 3,054 posts
- 7. But Jesus 21.6K posts
- 8. FEMA 73.4K posts
- 9. Sam Harris 3,580 posts
- 10. NO CAP 15K posts
- 11. FREE HAT 1,750 posts
- 12. #Survivor49 4,014 posts
- 13. Lute 88K posts
- 14. LANDRY 2,941 posts
- 15. Derik Queen 4,860 posts
- 16. Fulani 77.6K posts
- 17. Pink Floyd 2,791 posts
- 18. #LAShortnSweet 4,111 posts
- 19. Crockett 55.5K posts
- 20. #CMAawards 5,664 posts
You might like
-
Sherene Loi, MD
@LoiSher -
Antonio Giordano, MD PhD
@antgiorda -
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Breast International Group
@BIGxResearch -
FabriceAndre
@FAndreMD -
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc -
Lisa Carey, MD, ScM, FASCO
@DrLisaCarey -
Evandro de Azambuja, MD, PhD
@E_de_Azambuja -
Kevin Punie
@kevinpunie -
Giampaolo Bianchini
@BianchiniGP -
Elisa Agostinetto
@ElisaAgostinett -
Michail ignatiadis
@MIgnatiadis -
Lorenzo Gerratana
@LGerratana -
G Curigliano MD PhD
@curijoey -
Maria Vittoria Dieci
@vitti10
Something went wrong.
Something went wrong.